8-K: Perrigo Announces Executive Leadership Transition in Global Operations and Supply Chain

Perrigo Company plc has announced the retirement of its Executive Vice President of Global Operations and Supply Chain, Ronald Janish, and the appointment of industry veteran Matt Winterman as his successor, effective June 23, 2025.

Summary

• Perrigo Company plc announced the planned retirement of Ronald Janish, Executive Vice President, Global Operations and Supply Chain, effective June 23, 2025, with an advisory role until September 30, 2025.
• Matt Winterman has been appointed as the new Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025.
• Mr. Janish will receive a lump sum severance payment equal to 2.5 times his base salary and target annual bonus, statutory redundancy payments, and continued vesting of equity awards.
• The total termination payment for Mr. Janish amounts to €2,557,640.76 (gross), including a statutory redundancy payment of €37,678.85 (net), accrued holiday pay of €39,475.96 (gross), an ex gratia termination payment of €2,419,312.50 (gross), and a pension allowance of USD $65,000 / €61,173.45 (net).
• Mr. Janish will also receive a net lump sum of €20,000 for U.S. relocation expenses, company-paid tax preparation for 2025 and 2026, and a discretionary Long-Term Incentive Plan grant of $850,000 in June 2025.
• Mr. Winterman brings over 20 years of global supply chain and strategy leadership, having previously served as SVP of Global Supply Chain and Strategy at AstraZeneca, overseeing a $54 billion supply chain across 5,000 SKUs.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to the appointment of a highly experienced successor to a critical role, ensuring continuity and strategic advancement. The planned nature of the retirement and the smooth transition process contribute to this positive outlook. The significant severance package is a minor negative financial impact but is expected for a long-serving executive.

Positives

• The appointment of Matt Winterman, an industry veteran with over 20 years of global supply chain and strategy leadership from companies like AstraZeneca, Roche, and GSK, is expected to advance Perrigo's manufacturing and supply chain capabilities.
• The transition is planned to be smooth, with Mr. Janish continuing in an advisory capacity until September 30, 2025, to ensure continuity.
• Ronald Janish's distinguished career at Perrigo, including his instrumental role in the Supply Chain Reinvention program and ensuring operational resilience during the COVID-19 pandemic, highlights a strong foundation for the incoming executive.

Negatives

• The severance package for Ronald Janish is substantial, totaling over €2.5 million (gross) plus additional benefits, which represents a significant expense.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause actual results, performance, or achievements to be materially different from current expectations, assumptions, estimates, and projections.

Future Outlook

Perrigo anticipates that Matt Winterman's expertise will be pivotal in advancing its next-generation manufacturing and supply chain capabilities, supporting the execution of its long-term consumer self-care strategy, and ensuring operational excellence across its broad portfolio of molecules, dosage forms, and price coverage.

Management Comments

• Patrick Lockwood-Taylor, President and CEO, stated: 'We are deeply grateful to Ron for his more than two decades of outstanding leadership and unwavering commitment to Perrigo. His vision and execution have been instrumental in transforming our global supply chain and ensuring operational resilience, especially during some of the most challenging times in recent history.'
• Patrick Lockwood-Taylor also commented: 'We are pleased to welcome Matt to Perrigo and our executive leadership team. His expertise will be pivotal in advancing Perrigo’s next-generation manufacturing and supply chain capabilities. Matts leadership will support the execution of our long-term consumer self-care strategy, ensuring operational excellence across a broad portfolio of molecules, dosage forms and price coverage.'
• Matt Winterman stated: 'I am honored to join the incredible team at Perrigo. I look forward to driving industry-leading initiatives to ensure our supply chain network operates at the highest standards, continuing to consistently and reliably deliver our self-care solutions to consumers and customers every day.'

Industry Context

Perrigo, a leading pure-play self-care company, is reinforcing its operational leadership by bringing in a seasoned executive from the broader pharmaceutical industry. This move aligns with a trend of consumer health companies focusing on robust and efficient supply chains to meet global demand and navigate complex regulatory environments, especially given the lessons learned from recent global disruptions.

Comparison to Industry Standards

• Matt Winterman's previous role as SVP of Global Supply Chain and Strategy at AstraZeneca, where he oversaw a $54 billion supply chain across 5,000 SKUs, demonstrates experience managing operations at a scale comparable to or exceeding many industry leaders.
• His prior experience at Roche Holding AG and GSK plc further indicates a background in large-scale, complex global supply chain management within the pharmaceutical and healthcare sectors, suggesting Perrigo is recruiting top-tier talent aligned with global benchmarks for operational excellence.

Management Changes

Legal Proceedings

• The Compromise Waiver Agreement between Perrigo Corporation DAC and Ronald Janish serves to settle all outstanding claims the employee may have against the Company or any Group Company arising from his employment and its termination, which is a standard legal practice for executive departures.

Related Party Transactions

• The Compromise Waiver Agreement details the severance and other payments to Ronald Janish, a departing executive, which constitutes a transaction with a related party (former officer).

Stakeholder Impact

• Shareholders: Will bear the cost of the severance package and benefit from the strategic direction and operational improvements expected from the new leadership.
• Employees: Experience a change in senior leadership within the Global Operations and Supply Chain function, potentially leading to new strategies and initiatives.
• Customers/Consumers: The appointment of a highly experienced supply chain leader aims to ensure continued and improved reliability in delivering self-care solutions.

Next Steps

• Ronald Janish will continue in an advisory capacity until September 30, 2025, to ensure a smooth transition.
• Matt Winterman will assume his new role as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025.
• Ronald Janish will complete transition of duties by July 15, 2025, and resign from all directorships by August 28, 2025.

Key Dates

Recommendation

Keywords

Perrigo, PRGO, Management Change, Executive Retirement, Supply Chain Leadership, Global Operations, Consumer Self-Care, Pharmaceutical Supply Chain, Executive Appointment, SEC Filing, 8-K